MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Decreases Stake in Pfizer Inc. (NYSE:PFE)

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH decreased its position in Pfizer Inc. (NYSE:PFE) by 15.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,073,794 shares of the biopharmaceutical company’s stock after selling 385,034 shares during the period. Pfizer accounts for 1.5% of MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s investment portfolio, making the stock its 26th biggest holding. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Pfizer were worth $52,550,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Sound Income Strategies LLC boosted its holdings in Pfizer by 3.4% in the 1st quarter. Sound Income Strategies LLC now owns 790,953 shares of the biopharmaceutical company’s stock worth $20,043,000 after buying an additional 26,131 shares during the period. Foster Victor Wealth Advisors LLC boosted its holdings in Pfizer by 6.1% in the 1st quarter. Foster Victor Wealth Advisors LLC now owns 598,475 shares of the biopharmaceutical company’s stock valued at $15,165,000 after purchasing an additional 34,440 shares during the period. Ritholtz Wealth Management boosted its holdings in Pfizer by 54.7% in the 1st quarter. Ritholtz Wealth Management now owns 51,799 shares of the biopharmaceutical company’s stock valued at $1,313,000 after purchasing an additional 18,309 shares during the period. Wilsey Asset Management Inc. boosted its holdings in Pfizer by 6.6% in the 1st quarter. Wilsey Asset Management Inc. now owns 941,729 shares of the biopharmaceutical company’s stock valued at $23,863,000 after purchasing an additional 58,372 shares during the period. Finally, Missouri Trust & Investment Co boosted its holdings in Pfizer by 3.0% in the 1st quarter. Missouri Trust & Investment Co now owns 53,327 shares of the biopharmaceutical company’s stock valued at $1,351,000 after purchasing an additional 1,570 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 1.3%

Shares of NYSE PFE opened at $24.51 on Friday. The firm’s 50 day moving average price is $23.06 and its 200-day moving average price is $24.95. The company has a market cap of $139.35 billion, a PE ratio of 17.38, a P/E/G ratio of 0.64 and a beta of 0.57. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. During the same period in the previous year, the company earned $0.82 earnings per share. The firm’s quarterly revenue was down 7.8% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.02%. Pfizer’s dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

Several analysts have recently weighed in on PFE shares. The Goldman Sachs Group restated a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 target price on the stock. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. Finally, Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, four have given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.